[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"coronary-stenosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:coronary-stenosis":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,19,0,[8,45,79,110,165,189,209,236,260,286,315,334,363,391,418,441,467,494,521],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100330918","iris--desyne-x2-in-the-iris-des-registry-100330918",false,"NCT03588481","IRIS- DESyne X2 in the IRIS-DES Registry","Evaluation of Effectiveness and Safety of DESyne X2 in Routine Clinical Practice; A Multicenter, Prospective Observational Study","IRIS DESyne X2","Inclusion Criteria:\n\n* Age 19 and more\n* Intervention with DeSyne X2 drug-eluting coronary stent\n* Agreed with written informed consent form\n\nExclusion Criteria:\n\n* Intervention with DeSyne X2 drug-eluting coronary stent and other drug eluting stent at the same time\n* Life expectancy of 1year and under\n* Cardiac shock","ALL","19 Years",{"count":20,"type":21},1000,"ESTIMATED","OBSERVATIONAL","This study evaluates effectiveness and safety of DESyne X2 in Routine Clinical Practice.",[25,26,27],"Coronary Stenosis","Coronary Occlusion","Coronary Disease",[29,30,31],"PCI","DES","real world","RECRUITING","2026-06-23",{"date":35,"type":36},"2026-06-24","ACTUAL",{"date":38,"type":36},"2018-11-28",{"date":40,"type":21},"2031-12-31",{"name":42,"class":43},"Seung-Jung Park","OTHER",6,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":78},"100641370","effect-of-mobile-based-home-cardiac-rehabilitation-on-coronary-plaque-100641370","NCT07660419","Effect of Mobile-Based Home Cardiac Rehabilitation on Coronary Plaque","Effect of Mobile Internet Technology-Based Home Cardiac Rehabilitation on Coronary Artery Plaque in Patients With Mild to Moderate Stenosis","MHCRT","Inclusion Criteria:\n\n* 1.Diagnosis of mild-to-moderate coronary artery stenosis: presence of plaque in any coronary artery causing mild (\\\u003C50%) or moderate (50%-69%) luminal stenosis.\n\n  2.Age between 18 and 70 years. 3.Asymptomatic during exercise or recovery phases of cardiopulmonary assessment, including absence of angina, ST-segment depression, or complex arrhythmias at rest or during exercise.\n\n  4.Normal troponin levels. 5.Provided signed informed consent.\n\nExclusion Criteria:\n\n* 1\\. Severe coronary artery stenosis. 2.Presence of severe respiratory or cardiovascular diseases (e.g., acute myocardial infarction, acute tachyarrhythmia, pulmonary edema, severe aortic stenosis).\n\n  3.Angina symptoms or signs during low-intensity exercise (\\\u003C5 METs) or recovery. 4.Complex arrhythmias at rest or during exercise. 5.Hemodynamic abnormalities during exercise (e.g., failure of systolic blood pressure or heart rate to increase, or a decrease in blood pressure with increased exercise workload).\n\n  6.Severe psychological disorders. 7.Left ventricular ejection fraction (LVEF) \\\u003C 40%. 8.Elevated troponin levels. 9.Inability to undergo cardiopulmonary exercise testing due to neuromuscular or musculoskeletal disorders.\n\n  10.Presence of other severe comorbidities. 11.Refusal to sign informed consent.","18 Years","70 Years",{"count":56,"type":21},176,"INTERVENTIONAL",[59],"NA","This single-center, randomized controlled trial aims to evaluate the efficacy of a mobile internet-based, home-based cardiac rehabilitation program in patients with mild to moderate coronary artery stenosis. A total of 176 eligible participants will be randomized to receive either a personalized lifestyle intervention via a mobile platform or routine clinical care. The primary endpoint is the change in non-calcified coronary plaque volume, as measured by coronary computed tomography angiography (CTA) at 12 months. Participants will be followed for a total of 36 months to comprehensively assess the long-term impact of this digital lifestyle intervention on plaque progression and cardiovascular outcomes.",[62,25],"Coronary Artery Disease (CAD)",[62,64,65,25,66,67],"Home-based Cardiac Rehabilitation","Mobile Health (mHealth)","Non-calcified Plaque","Coronary Computed Tomography Angiography (CCTA)","2026-06-16",{"date":70,"type":36},"2026-06-22",{"date":72,"type":36},"2024-12-31",{"date":74,"type":21},"2027-12-31",{"name":76,"class":77},"China National Center for Cardiovascular Diseases","OTHER_GOV",1,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":57,"phases":89,"briefSummary":90,"conditions":91,"keywords":94,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":78},"100642807","qfr-guided-virtual-stenting-for-preprocedural-physiological-optimization-of-percutaneous-coronary-intervention-a-randomized-controlled-trial-100642807","NCT07635407","QFR-Guided Virtual Stenting for Preprocedural Physiological Optimization of Percutaneous Coronary Intervention: A Randomized Controlled Trial","A Multicenter, Prospective, Randomized Controlled Trial of Preprocedural Physiological Optimization of Percutaneous Coronary Intervention Using Coronary Imaging-Physiology Fusion-Based Virtual Stenting Technology","FAVOR-Virtual","Inclusion Criteria:\n\n* Age ≥18 years.\n* Diagnosis of coronary artery disease requiring percutaneous coronary intervention (PCI) according to current clinical practice.\n* Presence of at least one target coronary lesion considered suitable for PCI and evaluable by angiography-derived Quantitative Flow Ratio (QFR).\n* Ability to undergo coronary angiography and PCI. Provision of written informed consent before study participation.\n\nExclusion Criteria:\n\n* Contraindications to PCI or inability to undergo coronary intervention. Severe renal dysfunction or other conditions making angiographic procedures unsuitable.\n* High bleeding risk judged by investigators.\n* Inability to complete follow-up or comply with study procedures.\n* Life expectancy less than 1 year due to non-cardiovascular comorbidities.\n* Participation in another interventional clinical trial that may interfere with study outcomes.\n* Coronary anatomy unsuitable for QFR-based virtual stenting analysis.\n* Any condition judged by investigators to make study participation inappropriate.",{"count":88,"type":21},1472,[59],"Coronary angiography-guided percutaneous coronary intervention (PCI) remains the standard treatment strategy for patients with coronary artery disease; however, suboptimal post-PCI physiological outcomes remain common and are associated with adverse cardiovascular prognosis. Quantitative Flow Ratio (QFR)-based virtual stenting technology enables simulation of post-intervention coronary physiology before PCI and may facilitate individualized optimization of stent implantation strategies.\n\nThis multicenter, prospective, randomized controlled trial aims to evaluate whether preprocedural physiological optimization of PCI using coronary imaging-physiology fusion-based virtual stenting technology improves clinical outcomes compared with conventional angiography-guided PCI. Eligible patients undergoing PCI for coronary artery disease will be randomized in a 1:1 ratio to either virtual stenting-guided PCI optimization or standard angiography-guided PCI.\n\nThe primary endpoint is major adverse cardiovascular events (MACE), defined as a composite of all-cause death, nonfatal myocardial infarction, and ischemia-driven repeat revascularization within 1 year after PCI. Secondary endpoints include post-PCI physiological optimization, cardiovascular death or nonfatal myocardial infarction, repeat revascularization, quality of life, procedural safety, and health economic outcomes.",[92,25,93],"Coronary Artery Disease","Ischemic Heart Disease",[95,96,97,98,92,99,100],"Percutaneous Coronary Intervention","Quantitative Flow Ratio","Virtual Stenting","Coronary Physiology","Physiological Optimization","Functional Revascularization","NOT_YET_RECRUITING","2026-06-07",{"date":104,"type":36},"2026-06-09",{"date":106,"type":21},"2026-07-01",{"date":108,"type":21},"2028-12-31",{"name":76,"class":77},{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":116,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":118,"targetDuration":4,"studyType":57,"phases":120,"briefSummary":121,"conditions":122,"keywords":145,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":78},"100557242","single-vs-dual-antiplatelet-therapy-in-elderly-or-hbr-patients-undergoing-percutaneous-intervention-with-dcb-piccoleto-iv-epic-38-100557242","NCT06535568","Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO IV-EPIC 38)","International, Multicenter, Investigator-driven Randomized Clinical Trial to Assess the Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With Drug-coated Balloons (PICCOLETO IV-EPIC 38)","PIV-EPIC","Inclusion Criteria:\n\nMale and female patients who meet the following criteria:\n\n* Age ≥ 75 years or age ≥ 18 years at high bleeding risk;\n* Successful PCI with Essential Pro DCB just performed, in 1, 2 or 3 coronary vessels;\n* Stable or unstable coronary syndromes;\n* De novo coronary lesions in vessels with diameter ≥2.0 and ≤4.0 mm (visual estimation);\n* Informed consent to participate in the study given by the patient or impartial witness.\n\nExclusion Criteria:\n\n* Stent implantation during index or recent (\\\u003C6 months) procedure;\n* Known (and untreatable) hypersensitivity or contraindication to aspirin, heparin, clopidogrel, paclitaxel or contrast media, or any of their excipient which cannot be adequately pre-medicated;\n* Pregnancy at the time of hospitalization;\n* Patients participating in another clinical study in which an investigational drug or device was administered within 30 days of screening or within the 5 half-lives of the study drug, whichever is longer;\n* ST-elevation myocardial infarction;\n* Life expectancy \\\u003C12 months;\n* Left ventricular ejection fraction \\\u003C30%;\n* Visible thrombus at lesion site;\n* Target lesion\u002Fvessel with any of the following characteristics:\n\n  * severe and\u002For \\>270° calcification of the target vessel, also proximal to the lesion (intravascular imaging not mandatory);\n  * left main stem stenosis \\>50%;\n  * target lesion is in the left main stem;\n  * chronic total occlusion with anticipated necessity of retrograde approach;\n  * lesion is in a bypass graft.\n* History of asthma induced by the administration of salicylates or substances with a similar action, notably non-steroidal anti-inflammatory medicines (NSAIDs);\n* History of gastrointestinal perforation, ulceration, or bleeding (peptic ulcer bleeding-PUBs) related to previous use of NSAIDs or anticoagulant medications, or intracranial hemorrhage;\n* Acute gastrointestinal ulcers;\n* Hemorrhagic diathesis (including known bleeding disorders or ongoing active bleeding);\n* Severe renal impairment (eGFR \\\u003C 30 mL\u002Fmin);\n* Severe hepatic impairment (Child-Pugh C), with elevated liver enzymes (ALT\u002FAST \\> 2 x ULN or total bilirubin \\>1.5 x ULN);\n* Severe cardiac failure (NYHA grade III or IV);\n* Combination with methotrexate at doses of 15 mg\u002Fweek or more;\n* Patients with baseline neutrophil counts \\\u003C 1500 cells\u002Fmm³;\n* Breastfeeding women;\n* Full-blown thyrotoxicosis;\n* Patients with a very high risk of thrombosis.",{"count":119,"type":21},576,[59],"This international, multicenter, open-label, randomized clinical trial evaluates the safety and efficacy of single antiplatelet therapy (SAPT) compared to dual antiplatelet therapy (DAPT) in elderly or high bleeding risk patients undergoing percutaneous coronary intervention (PCI) with the latest generation drug-coated balloon (DCB). The study includes patients with stable or unstable coronary syndromes and aims to assess rates of ischemic and bleeding adverse events.",[27,123,124,125,126,127,128,92,129,25,130,131,132,133,134,135,136,137,138,139,140,141,142,143,144],"Heart Diseases","Cardiovascular Diseases","Myocardial Ischemia","Atherosclerosis","Arterial Occlusive Diseases","Vascular Diseases","Acute Coronary Syndrome","Molecular Mechanisms of Pharmacological Action","Enzyme Inhibitors","MTOR Inhibitors","Protein Kinase Inhibitors","Physiological Effects of Drugs","Immunosuppressive Agents","Antineoplastic Agents","High Bleeding Risk","Single Antiplatelet Therapy","Dual Antiplatelet Therapy","Cyclooxygenase Inhibitors","P2Y12 Inhibitor","Platelet Aggregation Inhibitors","Aspirin","Clopidogrel",[146,147,148,149,150,151,152,153,154,155],"DCB","Angioplasty","Paclitaxel","Antiplatelet treatment","Single antiplatelet therapy (SAPT)","Dual antiplatelet therapy (DAPT)","High bleeding risk (HBR)","MACE","Native CAD","stable or unstable coronary syndromes","2026-01-21",{"date":158,"type":36},"2026-01-22",{"date":160,"type":36},"2026-01-10",{"date":162,"type":21},"2028-02-20",{"name":164,"class":43},"Fondazione Ricerca e Innovazione Cardiovascolare ETS",{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":171,"eligibilityCriteria":172,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":173,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":175,"conditions":176,"keywords":178,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":188},"100318610","evaluation-of-effectiveness-and-safety-of-rotational-atherectomy-in-routine-clinical-practice-100318610","NCT03427996","Evaluation of Effectiveness and Safety of Rotational Atherectomy in Routine Clinical Practice","Evaluation of Effectiveness and Safety of Rotational Atherectomy in Routine Clinical Practice; A Multicenter, Prospective Observational Study","IRIS-ROTA","Inclusion Criteria:\n\n* Patients ≥ 19 years old\n* Patients who received rotational atherectomy\n* The patient or guardian agrees to the study protocol and the schedule of clinical follow-up and provides informed, written consent, as approved by the appropriate Institutional Review Board\u002FEthics Committee of the respective clinical site.\n\nExclusion Criteria:\n\n* Life expectancy \\\u003C1y",{"count":174,"type":21},500,"This study evaluates the effectiveness and safety rotational atherectomy in routine clinical practice.",[177,25],"Atherosclerosis, Coronary",[179],"rotational atherectomy","2025-12-28",{"date":182,"type":36},"2026-01-02",{"date":184,"type":36},"2018-09-04",{"date":186,"type":21},"2034-12-31",{"name":42,"class":43},8,{"id":190,"slug":191,"hasResults":11,"nctId":192,"briefTitle":193,"officialTitle":193,"acronym":194,"eligibilityCriteria":195,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":196,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":198,"conditions":199,"keywords":201,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":204,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":208,"locationsCount":78},"100317422","asan-medical-center-myocardial-infarction-registry-100317422","NCT03412435","Asan Medical Center Myocardial Infarction Registry","Asan-MI","Inclusion Criteria:\n\n* All consecutive acute myocardial infarction patients diagnosed through coronary angiography",{"count":197,"type":21},5000,"This study evaluates long-term outcome of patients diagnosed as acute myocardial infarction and treated with medication, coronary artery bypass surgery and percutaneous coronary intervention in Asan medical center, Korea.",[200,25],"Myocardial Infarction, Acute",[202,203],"Acute myocardial infarction","Myocardial infarction",{"date":182,"type":36},{"date":206,"type":36},"2018-04-27",{"date":40,"type":21},{"name":42,"class":43},{"id":210,"slug":211,"hasResults":11,"nctId":212,"briefTitle":213,"officialTitle":214,"acronym":4,"eligibilityCriteria":215,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":216,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":218,"conditions":219,"keywords":224,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":4},"100611387","disease-characteristics-of-r-cad-100611387","NCT07239921","Disease Characteristics of R-CAD","Disease Characteristics of Rapidly Progressive Coronary Artery Disease (R-CAD): A Case-control Study","Inclusion Criteria:\n\nCase Group (R-CAD patients):\n\n1. 18 years of age or older, male or female.\n2. Negative results of urine or blood pregnancy test for females with childbearing potential (not post-menopausal or surgically sterile).\n3. Prior history of coronary revascularization (PCI or CABG).\n4. Receiving standard treatment for secondary prevention of AS-CAD after the latest coronary revascularization.\n5. Rapidly progressive myocardial ischemia leading to hospitalization and\u002For coronary revascularization:\n\n   1. Typical symptoms of angina (Canadian Cardiovascular Society \\[CCS\\] classification III-IV) and non-invasive evidence of myocardial ischemia; and\n   2. Occurred within 6 months of the latest ischemia-driven hospitalization and\u002For coronary revascularization.\n6. Rapidly progressive coronary lesions leading to myocardial ischemia:\n\n   1. Angiographic evidence of new-onset or worsened coronary de novo or restenotic lesions relevant to myocardial ischemia, and\n   2. Occurred within 6 months of the latest ischemia-driven coronary angiography and\u002For revascularization.\n\nControl Group (NR-CAD patients):\n\n1. 35 to 75 years old\\*, male or female. (\\* Based on the age distribution characteristics of patients who have been diagnosed as R-CAD.)\n2. Negative results of urine or blood pregnancy test for females with childbearing potential (not post-menopausal or surgically sterile).\n3. Currently, at 12±6 months after the latest PCI.\n4. Receiving standard treatment for secondary prevention of AS-CAD after the latest PCI.\n5. Coronary angiography and\u002For optical coherence tomography (OCT) performed during the index hospitalization.\n6. No evidence of rapidly progressive myocardial ischemia and coronary lesions, i.e., not fulfilling items 5) and 6) of the inclusion criteria for R-CAD.\n\nExclusion Criteria:\n\n1. Receiving immunosuppressive therapy within 6 months.\n2. Coronary restenosis due to mechanical factors (stent under-expansion, stent mal-apposition, stent rupture, et al).\n3. Other moderate to severe heart diseases (congenital heart disease, valvular heart disease, myocarditis, cardiomyopathy, pericardial diseases, pulmonary hypertension, heart failure, arrhythmia, et al).\n4. Active malignancy (diagnosed within 12 months or with ongoing requirement for treatment).\n5. Vital organ failure.\n6. Life expectancy \\\u003C 1 year.\n7. In pregnancy or breast-feeding, or with intention to be pregnant during the study period.\n8. Risk of non-compliance (history of drug addiction or alcohol abuse, et al).\n9. Previous enrollment in this study.\n10. Participation in another study within 30 days.\n11. Involvement in the planning and conduct of this study (applying to investigators, contract research organization staffs, study site staffs, et al).\n12. Any condition, which in the opinion of the investigators, would make it unsuitable for the patient to participate in this study.",{"count":217,"type":21},52,"The present case-control study is designed to investigate the disease characteristics of rapidly progressive coronary artery disease (R-CAD) by comparing the demographics, clinical features, lab results, imaging findings, and prior treatment between patients in the case group (approximately 34 patients with R-CAD) and those in the control group (approximately 18 patients with non-rapidly progressive coronary artery disease \\[NR-CAD\\]).",[92,220,25,221,222,223,95],"Coronary Artery Disease Progression","Coronary Restenosis","Coronary Stent Occlusion","Myocardial Revascularization",[92,25,221,223,95,225,226],"Disease Progression","Disease Attributes","2025-11-21",{"date":229,"type":36},"2025-11-28",{"date":231,"type":21},"2025-11",{"date":233,"type":21},"2026-10",{"name":235,"class":43},"Peking Union Medical College Hospital",{"id":237,"slug":238,"hasResults":11,"nctId":239,"briefTitle":240,"officialTitle":240,"acronym":241,"eligibilityCriteria":242,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":243,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":245,"conditions":246,"keywords":4,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":78},"100542900","clinical-evaluation-of-radiation-reduction-for-optimized-safety-100542900","NCT06348875","Clinical Evaluation of Radiation Reduction for Optimized Safety","CERROS","Inclusion Criteria:\n\n* Referred for clinically indicated coronary angiography\n* ≥18 years of age\n* Not pregnant\n* English speaking\n* Not imprisoned\n* Able to provide written informed consent\n\nExclusion Criteria:\n\n* Hemodynamically or electrically unstable.\n* Indication for coronary angiography is emergent, including ST-segment elevation myocardial infarction\n* History of coronary artery bypass grafting\n* An eGFR \\\u003C60\n* Pregnant or lactating\n* A BMI of 45 or greater\n* Any other factor that the investigator feels would put the patient at increased risk or otherwise make the patient unsuitable for participation in the protocol",{"count":244,"type":21},50,"The primary objective of this study is to determine whether a reduced radiation protocol (RRP) in which angiograms are acquired at ultralow radiation doses and then processed using spatiotemporal enhancement software can produce similar quality angiographic images as compared with standard techniques.",[92,247,27,25,248,249],"Myocardial Infarction","Angina Pectoris","Chest Pain","2025-11-12",{"date":252,"type":36},"2025-11-13",{"date":254,"type":21},"2026-02-15",{"date":256,"type":21},"2026-07-15",{"name":258,"class":259},"Angiowave Imaging","INDUSTRY",{"id":261,"slug":262,"hasResults":11,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":266,"eligibilityCriteria":267,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":268,"targetDuration":4,"studyType":57,"phases":270,"briefSummary":271,"conditions":272,"keywords":274,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":277,"startDateStruct":279,"completionDateStruct":281,"leadSponsor":283,"locationsCount":285},"100411186","staged-complete-revascularization-for-coronary-artery-disease-vs-medical-management-alone-in-patients-with-as-undergoing-transcatheter-aortic-valve-replacement-100411186","NCT04634240","Staged Complete Revascularization for Coronary Artery Disease vs Medical Management Alone in Patients With AS Undergoing Transcatheter Aortic Valve Replacement","A Randomized, Comparative Effectiveness Study of Staged Complete Revascularization With Percutaneous Coronary Intervention to Treat Coronary Artery Disease vs Medical Management Alone in Patients With Symptomatic Aortic Valve Stenosis Undergoing Elective Transfemoral Transcatheter Aortic Valve Replacement: The COMPLETE TAVR Study","COMPLETE TAVR","Inclusion Criteria:\n\n\\- Symptomatic aortic valve stenosis prior to TAVR (NYHA Functional Class ≥ 2 OR Abnormal exercise test with severe SOB, abnormal BP response, or arrhythmia)\n\nAND\n\n\\- CAD defined as: at least 1 coronary artery lesion of ≥70% visual angiographic diameter stenosis in a native segment ≥2.5 mm in diameter that is not a CTO and is amenable to treatment with PCI\n\nAND\n\n\\- Consensus by the Local Multidisciplinary Heart Team that the patient is suitable for elective transfemoral TAVR with a balloon expandable transcatheter heart valve AND would receive a bypass with an anastomosis distal to the coronary artery lesion(s) if they were undergoing SAVR.\n\nLocal Multidisciplinary Heart Teams are expected to follow current clinical guidelines for selection of patients for TAVR with an eligible patient generally expected to have:\n\n\\[AVA ≤ 1.0 cm2 OR AVA index ≤ 0.6 cm2\u002Fm2\\]\n\nOR\n\n\\[Jet velocity ≥ 4.0 m\u002Fs OR mean gradient ≥ 40 mmHg\\]\n\nOR\n\npatients without these criteria may undergo TAVR if the Local Multidisciplinary Heart Team concludes it is appropriate.\n\nAND\n\n\\- Successful transfemoral TAVR, defined as the implantation of a single transcatheter aortic valve within the past 96 hours with freedom from more than minimal aortic insufficiency, stroke, or major vascular complications.\n\nExclusion Criteria:\n\n* PCI already performed within 90 days prior to TAVR or at the same time as the index transfemoral TAVR procedure\n* Planned PCI of coronary artery lesion(s)\n* Planned surgical revascularization of coronary artery lesion(s)\n* Non-cardiovascular co-morbidity reducing life expectancy to \\\u003C 5 years\n* Any factor precluding 5-year follow-up\n* Prior coronary artery bypass grafting surgery or surgical valve replacement\n* Severe mitral regurgitation (\\> 3+)\n* Severe left ventricular dysfunction (LVEF \\\u003C 30%)\n* Low coronary takeoff (high risk for coronary obstruction)\n* Acute myocardial infarction within 90 days\n* Stroke or transient ischemic attack within 90 days\n* Renal insufficiency (eGFR \\\u003C 30 ml\u002Fmin) and\u002For renal replacement Rx\n* Hemodynamic or respiratory instability",{"count":269,"type":21},4000,[59],"Patients undergoing transcatheter aortic valve replacement (TAVR) often have concomitant coronary artery disease (CAD) which may adversely affect prognosis. There is uncertainty about the benefits and the optimal timing of revascularization for such patients. There is currently clinical equipoise regarding the management of concomitant CAD in patients undergoing TAVR. Some centers perform routine revascularization with percutaneous coronary intervention (PCI) (either before or after TAVR), while others follow an alternative strategy of medical management.\n\nThe potential benefits and optimal timing of PCI in these patients are unknown. As TAVR expands to lower risk patients, and potentially becomes the preferred therapy for the majority of patients with severe aortic stenosis, the optimal management of concomitant coronary artery disease will be of increasing importance.\n\nThe COMPLETE TAVR study will determine whether, on a background of guideline-directed medical therapy, a strategy of complete revascularization involving staged PCI using drug eluting stents to treat all suitable coronary artery lesions is superior to a strategy of medical therapy alone in reducing the composite outcome of Cardiovascular Death, new Myocardial Infarction, Ischemia-driven Revascularization or Hospitalization for Unstable Angina or Heart Failure.\n\nThe study will be a randomized, multicenter, open-label trial with blinded adjudication of outcomes. Patients will be screened and consented for elective transfemoral TAVR and randomized within 96 hours of successful balloon expandable TAVR.\n\nComplete Revascularization:\n\nStaged PCI using third generation drug eluting stents to treat all suitable coronary artery lesions in vessels that are at least 2.5 mm in diameter and that are amenable to treatment with PCI and have a ≥70% visual angiographic diameter stenosis. Staged PCI can occur any time from 1 to 45 days post successful transfemoral TAVR.\n\nVs. Medical Therapy Alone:\n\nNo further revascularization of coronary artery lesions.\n\nAll patients, regardless of randomized treatment allocation, will receive guideline-directed medical therapy consisting of risk factor modification and use of evidence-based therapies. The COMPLETE TAVR study will help address the current lack of evidence in this area. It will likely impact both the global delivery of health care and the management and clinical outcomes of all patients undergoing TAVR with concomitant CAD.",[273,92,25],"Aortic Stenosis",[275,95,92,273],"Transcatheter Aortic Valve Replacement","2025-07-22",{"date":278,"type":36},"2025-07-24",{"date":280,"type":36},"2020-12-19",{"date":282,"type":21},"2026-04-01",{"name":284,"class":43},"University of British Columbia",72,{"id":287,"slug":288,"hasResults":11,"nctId":289,"briefTitle":290,"officialTitle":291,"acronym":4,"eligibilityCriteria":292,"healthyVolunteers":11,"sex":17,"minAge":293,"maxAge":294,"enrollmentInfo":295,"targetDuration":4,"studyType":57,"phases":297,"briefSummary":298,"conditions":299,"keywords":4,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":307,"startDateStruct":309,"completionDateStruct":311,"leadSponsor":313,"locationsCount":4},"100591410","wearable-devices-assist-in-the-detection-screening-and-management-of-major-diseases-in-middle-aged-and-elderly-populations-100591410","NCT06980064","Wearable Devices Assist in the Detection, Screening, and Management of Major Diseases in Middle-aged and Elderly Populations","Wearable Devices Assist in the Detection, Screening, and Management of Major Diseases in Middle-aged and Elderly Populations: a Multicenter Randomized Controlled Trial","The inclusion criteria are as follows:\n\n1. Aged more than equal to 40 years, less than 69 years.\n2. Having at least one of the following conditions (with one risk factor for cardiovascular and cerebrovascular diseases):\n\n   ① Male ≥ 55 years old, female ≥ 65 years old; ② Smokers or those who quit smoking within the past 3 months prior to the visit; ③ Diabetes (type 1 or 2); ④ Hypertension (systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg) or currently taking antihypertensive medication; ⑤ Dyslipidemia: total cholesterol ≥ 5.18mmol\u002FL, triglycerides ≥ 1.70mmol\u002FL, high-density lipoprotein\\\u003C1.04mmol or low-density lipoprotein ≥ 3.37mmol\u002FL; ⑥ hsCRP\\>3.0 mg\u002FL; ⑦ 10-year ASCVD risk of 20% or more (calculated according to the formula designed in the PREVENT study)\n3. Agree to receive coronary CTA if suspected to have coronary artery stenosis.\n4. Voluntarily joined and signed the informed consent.\n\nThe exclusion criteria:\n\n1. Previously diagnosed with CAD or considered moderate to severe coronary stenosis (CAD-RADS grade 3 or above: stenosis degree of 50% or above) through coronary CTA or coronary angiography examination.\n2. Pregnant women or women planning to become pregnant within the next year.\n3. During the onset of the disease and needs in-hospital treatment.\n4. Tattoos or other substances that affect optical signals on the wrist.\n5. Severe arrhythmia patients, including third degree atrioventricular block, ventricular escape rhythm, severe sinus bradycardia, sick sinus syndrome, supraventricular tachycardia, ventricular tachycardia, atrial fibrillation, atrial flutter, ventricular fibrillation, ventricular flutter.\n6. Physical disability, blindness, and deafness.\n7. Allergic history of contrast agent containing iodine.","40 Years","69 Years",{"count":296,"type":21},800,[59],"The goal of this randomized controlled trial is to evaluate the effectiveness of wearable devices (Huawei smartwatches) in aiding the detection, and screening of major diseases (e.g., coronary artery disease, hypertension) in middle-aged and elderly populations aged 40-69 years with cardiovascular risk factors (e.g., smoking, diabetes, hypertension, dyslipidemia). The main questions it aims to answer are:\n\nDoes AI-assisted diagnosis using wearable device data improve the detection rate of coronary artery stenosis (CAD-RADS ≥3) compared to standard physician assessment without AI assistance?\n\nDoes the intervention reduce the incidence of coronary artery disease-related events (e.g., angina, myocardial infarction) within one year?\n\nResearchers will compare the intervention group (AI model-assisted diagnosis based on Huawei smartwatch data) with the control group (standard assessment) to determine if the AI-aided smartwatch approach enhances diagnostic accuracy and clinical outcomes.\n\nParticipants will:\n\n（Intervention group）Wear a Huawei smartwatch for 24 hours to collect physiological data (e.g., PPG signals, heart rate, motion).\n\nUndergo baseline assessments, including medical history review, physical exams, and laboratory tests.\n\nReceive a preliminary diagnosis from a general practitioner.\n\nComplete a follow-up evaluation after one year to track cardiovascular events and other disease outcomes.\n\nUndergo coronary CTA if suspected of coronary stenosis.",[25,300,301,302,303,304,305],"Cerebral Arterial Diseases","Hypertension","Parkinson Disease","Heart Failure","Peripheral Arterial Occlusive Disease","Thyroid Dysfunction","2025-05-16",{"date":308,"type":36},"2025-05-20",{"date":310,"type":21},"2025-06-01",{"date":312,"type":21},"2026-12-31",{"name":314,"class":43},"Tongji Hospital",{"id":316,"slug":317,"hasResults":11,"nctId":318,"briefTitle":319,"officialTitle":319,"acronym":4,"eligibilityCriteria":320,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":321,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":323,"conditions":324,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":325,"lastUpdatePostDateStruct":326,"startDateStruct":328,"completionDateStruct":330,"leadSponsor":332,"locationsCount":44},"100463243","physio-anatomy-clinical-data-collection-study-100463243","NCT05312164","Physio-Anatomy Clinical Data Collection Study","Inclusion Criteria:\n\n* Patients \\>18 years of age.\n* Patients provide written informed consent.\n* Clinical presentation consistent with suspected coronary disease.\n* Patients who are candidates for PCI and scheduled for coronary diagnostics in the cardiac catheter lab with the intent to perform a physiological assessment for de novo lesions with stenosis, if clinically indicated.\n\nExclusion Criteria:\n\n* Presence of acute ST Elevation Myocardial Infarction (STEMI) at the time of the cath lab procedure.\n* Contraindication for FFR examination or administration of vasodilators.\n* Bacteremia or sepsis.\n* Major coagulation system abnormalities.\n* Severe hemodynamic instability or shock.\n* Heart Failure NYHA Class IV.\n* Severe valvular heart disease.\n* Prior heart transplant.\n* Acute renal failure based on diagnostic practice of the treating physician at time of screening.\n* Patient is pregnant.\n* Patient is currently enrolled in another clinical study that may impact the results of this study.\n* Patient has other co-morbid condition(s) that, in the opinion of the Investigator, could limit their",{"count":322,"type":21},150,"This is an on-label clinical study design intended for the collection of three different types of interventional procedural data using FDA-cleared cardiac catheterization technologies and drugs, each used according to its product labeling and standard practice of medicine.",[25],"2025-03-19",{"date":327,"type":36},"2025-03-20",{"date":329,"type":36},"2022-03-14",{"date":331,"type":21},"2025-12-31",{"name":333,"class":259},"Gentuity, LLC",{"id":335,"slug":336,"hasResults":11,"nctId":337,"briefTitle":338,"officialTitle":339,"acronym":340,"eligibilityCriteria":341,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":342,"enrollmentInfo":343,"targetDuration":345,"studyType":22,"phases":4,"briefSummary":346,"conditions":347,"keywords":353,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":355,"lastUpdatePostDateStruct":356,"startDateStruct":358,"completionDateStruct":360,"leadSponsor":361,"locationsCount":4},"100559566","a-maajor-radiation-based-pci-study-in-stemi-and-nstemi-100559566","NCT06565793","A MAajor RAdiation-based PCI Study in STEMI and NSTEMI","The Impact of Radiation Delivered to the Patient and the Amount of Iodinated Contrast Medium Injected in Complex Versus Noncomplex Percutaneous Coronary Intervention.","MARAA","Inclusion Criteria:\n\n* The patient presents with a STEMI or NSTEMI requiring either a non-complex or complex PCI.\n\nExclusion Criteria:\n\n\\-","90 Years",{"count":344,"type":21},15630,"5 Years","In France and Italy, approximately 240,000 percutaneous coronary angioplasties (PCI) are performed annually, with an increasing number of complex procedures, including those involving the left coronary common trunk, a bifurcation, chronic occlusion, or requiring Rotablator Rotary Atherectomy (ARota). The medical literature lacks sufficient data regarding several key aspects of complex angioplasty. These include the epidemiological characteristics of patients undergoing such procedures, the impact of irradiation delivered and the quantity of iodine injected on these lengthy procedures, their procedural complication rate, and in-hospital mortality.",[348,349,25,350,351,26,352,92],"Myocardial Infarction (MI)","Radiation Toxicity","Coronary Thrombosis","Coronary Artery Calcification","Coronary Syndrome",[354],"PCI,DES, Radiation","2024-12-21",{"date":357,"type":36},"2024-12-27",{"date":359,"type":21},"2025-03-01",{"date":331,"type":21},{"name":362,"class":43},"Centre Cardiologique du Nord",{"id":364,"slug":365,"hasResults":11,"nctId":366,"briefTitle":367,"officialTitle":368,"acronym":369,"eligibilityCriteria":370,"healthyVolunteers":371,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":372,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":374,"conditions":375,"keywords":377,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":382,"lastUpdatePostDateStruct":383,"startDateStruct":385,"completionDateStruct":387,"leadSponsor":389,"locationsCount":78},"100552282","transit-time-flow-measurement-in-coronary-surgery-100552282","NCT06471062","Transit Time Flow Measurement in Coronary Surgery","Transit Time Flow Measurement in Coronary Surgery: The Mutual Influence of Collateral Flow Between Different Coronary Territories on Parameter Metrics","COLLATERAL","Inclusion Criteria:\n\n* age \\> 18 years;\n* informed consent acquired and registered;\n* patients who undergo coronary artery bypass grafting (with or without cardiopulmonary bypass);\n* patients with stable angina, unstable angina or acute coronary syndrome without elevation of the ST tract (NSTEMI)\n\nExclusion Criteria:\n\n* patients unable to give informed consent;\n* patients undergoing emergency surgery;\n* patients in unstable haemodynamic conditions or in need of pharmacological or mechanical support;\n* patients undergoing combined surgery;\n* patients undergoing single aortocoronary bypass surgery",true,{"count":373,"type":21},135,"Transit-time flowmetry (TTFM) allows grafts quality control during coronary artery bypass surgery by measuring the flow volume through them.\n\nTo date, many studies have deeply studied the predictive role on the graft outcomes of the various flowmetry-derived parameters. One of the least investigated aspects, however, is the mutual influence that two newly realized grafts can have. This possibility would be related to the presence of a more or less developed collateral circulation between the bypassed territories.\n\nThe purpose of this study is to assess whether a graft for a territory different than that provided by the left anterior descending artery (LAD) may affect the functionality (measured through flowmetry) of the left internal mammary artery - LAD graft.",[92,25,376],"Coronary Bypass Graft Stenosis",[378,379,380,381],"coronary artery bypass","Transit Time Flowmetry","Intraoperative epicardial high-frequency ultrasound (HFUS)","Coronary anastomosis patency","2024-11-26",{"date":384,"type":36},"2024-11-27",{"date":386,"type":21},"2024-11-20",{"date":388,"type":21},"2025-10-20",{"name":390,"class":43},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":392,"slug":393,"hasResults":11,"nctId":394,"briefTitle":395,"officialTitle":396,"acronym":4,"eligibilityCriteria":397,"healthyVolunteers":371,"sex":17,"minAge":53,"maxAge":398,"enrollmentInfo":399,"targetDuration":4,"studyType":57,"phases":401,"briefSummary":403,"conditions":404,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":409,"lastUpdatePostDateStruct":410,"startDateStruct":412,"completionDateStruct":414,"leadSponsor":416,"locationsCount":78},"100557767","phase-2-pbm-as-strategy-to-cabg-anemic-patients-bypass-graft-cabg-100557767","NCT06542393","PBM as Strategy to CABG Anemic Patients Bypass Graft (CABG)","Patient Blood Manegement (PBM) as Perioperative Strategy to Anemic Patients Who Will be Submitted to Coronary Artery Bypass Graft (CABG).","Inclusion Criteria:\n\n* Eletive surgery;\n* Only CABG as procedure;\n* Off pump CABG candidate.\n\nExclusion Criteria:\n\n* Age \\> 80 years;\n* Chronic dialytic kidney disease;\n* Chronic rheumatologic disease;\n* Men with Hb levels \\> 13 g\u002Fdl and \\\u003C 8g\u002Fdl;\n* Women with Hb levels \\> 12 g\u002Fdl and \\\u003C 8g\u002Fdl;\n* Presence of another heart disease requiring surgical intervention;\n* Presence of hepatic insufficiency;\n* Presence of any implantable electronic cardiac device in any cardiac chambers;\n* Pregnancy;\n* Diagnosis of malignant neoplasia;\n* Thrombophilias;\n* Need for Erythropoietin treatment due to any other disease.\n* Recent ischemic event (\\\u003C 3 months).\n* Ejection fraction \\\u003C30%.","80 Years",{"count":400,"type":21},120,[402],"PHASE2","Anemia poses risks during coronary artery bypass grafting (CABG), increasing complications and mortality rates. Blood transfusions in cardiac surgery have negative outcomes, prompting the use of erythropoietin in Patient Blood Management (PBM) to limit transfusion needs and enhance postoperative recovery. EPO can reduce blood component requirements, adverse events, and inflammation in anemic CABG patients. A study aims to minimize transfusions through a PBM anemia treatment protocol for CABG patients, comparing outcomes in three groups: a Control Group (CG), a Non-PBM Group (NPBMG) treated with blood components, and a PBM Group (GPBM) treated with EPO. Parameters include post-op stay, mortality, cardiovascular events, non-cardiovascular events, ICU time, mechanical ventilation duration, vasoactive drug use, inflammatory responses, and cardiac cell death. Analysis will consider demographic and clinical factors, with expectations that GPBM will yield superior results compared to NPBMG and similar or better outcomes than CG.",[405,27,92,25,26,406,407,408],"Anemia","Systemic Inflammatory Response","Bleeding","Epigenetic Disorder","2024-08-04",{"date":411,"type":36},"2024-08-07",{"date":413,"type":36},"2024-06-01",{"date":415,"type":21},"2026-06-01",{"name":417,"class":43},"Federal University of São Paulo",{"id":419,"slug":420,"hasResults":11,"nctId":421,"briefTitle":422,"officialTitle":423,"acronym":424,"eligibilityCriteria":425,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":426,"targetDuration":4,"studyType":57,"phases":428,"briefSummary":429,"conditions":430,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":432,"lastUpdatePostDateStruct":433,"startDateStruct":435,"completionDateStruct":437,"leadSponsor":439,"locationsCount":78},"100545033","study-of-microvascular-dysfunction-cfr-and-cardioprotective-effect-of-early-administration-of-esmolol-in-mi-100545033","NCT06376630","Study of Microvascular Dysfunction, CFR and Cardioprotective Effect of Early Administration of Esmolol in MI","Study of Microvascular Dysfunction, Coronary Flow Reserve and Cardioprotective Effect of Early Intravenously Administration of Esmolol in Patients With Myocardial Infarction","ESMO-VASCMI","Substudy evaluating cardioprotective effects of early iv administration of esmolol\n\nInclusion Criteria:\n\n* Diagnosed acute ST elevation MI, type 1, within the first 8 hours of disease onset;\n* Treating physician's decision not to administer metoprolol intravenously prior to primary PCI due to a high risk of complications (BP \\\u003C 120\u002F80 mm Hg at baseline examination, moderate evidence of heart failure (Killip 2) or a risk of its development (LV EF ≤ 30%), first degree AV block with PQ ≥ 0.25 ms, history of asthma or severe COPD etc.)\n* Signed Informed Consent to participate in the study\n\nExclusion Criteria:\n\n* severe heart failure (pulmonary edema; SCAI В-Е cardiogenic shock);\n* atrioventricular conduction abnormality higher than first degree, without a pacemaker;\n* sinus bradycardia with the heart rate of \\\u003C 60 bpm;\n* BP \\\u003C 100\u002F60 mm Hg.;\n* asthma in exacerbation;\n* history of a STEMI in the IRA basin;\n* clinically significant bleeding or hypovolemia;\n* hypersensitivity to esmolol;\n* pregnancy or lactation;\n* known severe comorbidities independently affecting prognosis (Child Pugh class C liver failure, active malignancies etc.);\n* contraindications to MRI (MR-incompatible pacemaker\u002Fimplanted cardioverter-defibrillator, cochlear implants, clips on brain vessels, foreign metal objects - bullets, intraorbital metal fragments, insulin pumps, body weight above 150 kg, history of allergies to gadolinium, claustrophobia);\n* severe dementia;\n* known severe comorbidities independently affecting prognosis (chronic renal or liver failure, active malignancies etc.);\n* complicated PCI, \"no reflow\" phenomenon on follow-up coronary angiography;\n* thrombolysis for AMI;\n* ECG evidence of spontaneous reperfusion on admission;\n* patient's refusal from participation in the study.\n\nSubstudy investigating coronary physiology\n\nInclusion Criteria:\n\n* Diagnosed MI, completed PCI for the IRA and multivessel Coronary Artery Disease with diameter stenosis of 50-85% in non-IRA.\n* Signed Informed Consent to participate in the study\n\nExclusion criteria:\n\n* History of coronary artery bypass grafting surgery;\n* Non-IRA lesions resulting in diameter stenosis of below 50% and above 85%, main left coronary artery (LCA) stenosis above 50%;\n* Chronic kidney disease stage 3b or above (glomerular filtration rate below 45 mL\u002Fmin\u002Fm2 according to the CKD-EPI equation);\n* History of a contrast-induced nephropathy (CIN) or a high CIN risk (calculated using the Mehran score);\n* History of allergies to iodine-containing medications;\n* Pregnancy or lactation;\n* Left ventricle ejection fraction ≤ 30%;\n* Known severe comorbidities independently affecting prognosis (chronic renal or liver failure, active malignancies etc.);\n* Early post-infarction angina;\n* Severe dementia;\n* Patient's refusal from participation in the study.",{"count":427,"type":21},300,[59],"Study rationale: to evaluate clinical and prognostic relevance of microvascular dysfunction, coronary flow reserve and cardioprotective effects of iv administration of esmolol in patients with myocardial infarction.\n\nFirst substudy is an open randomized trial evaluating the efficacy and safety of early intravenous administration of esmolol in patients with acute ST-segment elevation myocardial infarction (MI) and relative contraindications to administration of other intravenous β1-adrenergic blocker (metoprolol etс.). Сomparison group will include patients who have not received intravenous β1-adrenergic blocker. Secondary outcome in this substudy is the degree of microvascular obstruction and infarct size according to MRI with gadolinium delayed enhancement.\n\nSecond substudy examines the quantitative parameters of coronary physiology in patients with MI and multivessel disease. Changes of coronary physiology measurements over time ((iFR, Pd\u002FPa, FFR, delta FFR, gradient FFR per time unit (dFFR(t)\u002Fdt), pullback pressure gradient (PPG)) measured in the infarct-related artery and in non-infarct-related arteries with diameter stenosis of 50-85% immediately after the completion of a primary percutaneous coronary intervention and during a second hospitalization (30-45 days after STEMI) will be evaluated. The comparison changes of coronary physiology over time with presence of an MVO and infarct size determined by MRI. The model of calculating coronary flow reserve (CFR) based on tridimensional reconstruction of coronary arteries and coronary physiology parameters as measured during coronary angiography will be developed. The influence of coronary physiology parameters measured after complete myocardial revascularization by PCI, and derived CFR in patients with MI on long-term clinical outcomes will be evaluated, based on prospective data collection.\n\nPrimary composite outcome in all substudies will be the sum of adverse cardiac outcomes (congestive heart failure, episodes of recurrent congestive heart failure worsening resulting in hospitalizations, cardiac mortality, MI recurrences, unstable angina, urgent myocardial revascularization) within \\> 12 months post-infarction.\n\nSecondary composite outcome in all substudies is the degree of microvascular obstruction and infarct size evaluated by MRI with gadolinium delayed enhancement.",[247,25,431],"Coronary Microvascular Dysfunction","2024-04-18",{"date":434,"type":36},"2024-04-19",{"date":436,"type":36},"2024-01-29",{"date":438,"type":21},"2030-01-29",{"name":440,"class":77},"National Medical Research Center for Cardiology, Ministry of Health of Russian Federation",{"id":442,"slug":443,"hasResults":11,"nctId":444,"briefTitle":445,"officialTitle":446,"acronym":447,"eligibilityCriteria":448,"healthyVolunteers":11,"sex":17,"minAge":449,"maxAge":398,"enrollmentInfo":450,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":452,"conditions":453,"keywords":455,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":458,"lastUpdatePostDateStruct":459,"startDateStruct":461,"completionDateStruct":463,"leadSponsor":465,"locationsCount":78},"100363586","ifr-guided-coronary-artery-bypass-grafting-surgery-100363586","NCT04014140","iFR Guided Coronary Artery Bypass Grafting Surgery","Long-term Graft Patency Outcomes of LIMA-LAD Post-CABG Surgery Based on iFR Measurements.","iCABG","INCLUSION CRITERIA\n\n1. Age of 25 to 80 years of age\n2. Willing to participate and able to understand, read and sign the informed consent form (ICF) before standard of care elective CABG surgery\n3. Undergoing isolated first-time elective CABG surgery\n4. Available pre-operative angiography data with iFR measurements done during the pre-operative angiography\n\nEXCLUSION CRITERIA\n\n1. Emergency CABG surgery\n2. Ejection Fraction≤ 40%\n3. Severe valvular heart disease","25 Years",{"count":451,"type":21},100,"The expected outcome of better and improved patency of bypass grafts and its direct relation to pre-operative iFR measurements of stenosis as compared to direct visual physiology of stenosis in the coronary angiogram.\n\nTo establish the correlation between the use of intracoronary physiology and improved graft patency at 12 months for patients undergoing CABG surgery.\n\nIt is a minimum of 28 and a maximum of 100 patients single-centre proof or concept\u002F observational study\u002F pilot study.",[454,92,25],"Ischaemic Heart Disease",[456,457],"Instantaneous wave-free ratio (iFR)","Coronary Artery Bypass Grafting (CABG)","2023-11-20",{"date":460,"type":36},"2023-11-21",{"date":462,"type":36},"2022-04-25",{"date":464,"type":21},"2026-08-31",{"name":466,"class":43},"Prakash Punjabi",{"id":468,"slug":469,"hasResults":11,"nctId":470,"briefTitle":471,"officialTitle":472,"acronym":473,"eligibilityCriteria":474,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":475,"targetDuration":4,"studyType":57,"phases":477,"briefSummary":478,"conditions":479,"keywords":480,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":484,"lastUpdatePostDateStruct":485,"startDateStruct":487,"completionDateStruct":489,"leadSponsor":491,"locationsCount":493},"100499398","reverse-t-stenting-and-minimal-protrusion-with-external-minicrush-for-treatment-of-complex-coronary-bifurcation-100499398","NCT05782738","Reverse T-stenting and Minimal Protrusion With External Minicrush for Treatment of Complex Coronary Bifurcation","A Randomized Clinical Study Comparing Reverse T-stenting and Minimal Protrusion With External Minicrush for Treatment of Complex Coronary Bifurcation (T-REX Trial)","T-REX","Inclusion Criteria:\n\n* Patients \\>18 years old;\n* Patients with an indication of PCI, including Chronic Coronary syndrome (CCS) and Acute Coronary Syndrome (ACS), according to current guidelines recommendations; According to Medina and Definition criteria, patients with at least true and complex coronary lesions involved in coronary bifurcation.\n\nExclusion Criteria:\n\n* Patients that refused informed consent;\n* Patients without valid vascular access that could make unsafe PCI;\n* Patients with an expected life of less than one year;\n* Patients with scheduled major surgery that required prolonged DAPT interruption;\n* Pregnant patients;\n* Patients with DAPT contraindications.",{"count":476,"type":21},361,[59],"The Reverse T-stenting And Minimal Protrusion (Reverse TAP) is an up-front 2-stent technique that treats complex coronary bifurcation. Compared to crush techniques, it does not require crushing of the side branch stent but only minimal protrusion of the side branch stent before main vessel stenting. Nowadays, no studies compare the Reverse-TAP and the External Minicrush in treating complex coronary bifurcation, so eventually, procedural, clinical and safety differences remain unknown.",[92,25,27],[481,482,483],"Reverse TAP","External Minicrush","Coronary bifurcation lesion","2023-04-14",{"date":486,"type":36},"2023-04-19",{"date":488,"type":21},"2023-06-01",{"date":490,"type":21},"2029-06-01",{"name":492,"class":43},"San Luigi Gonzaga Hospital",5,{"id":495,"slug":496,"hasResults":11,"nctId":497,"briefTitle":498,"officialTitle":499,"acronym":500,"eligibilityCriteria":501,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":502,"targetDuration":4,"studyType":57,"phases":504,"briefSummary":505,"conditions":506,"keywords":507,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":512,"lastUpdatePostDateStruct":513,"startDateStruct":515,"completionDateStruct":517,"leadSponsor":518,"locationsCount":520},"100348722","comparison-of-optical-coherence-tomography-derived-minimal-lumen-area-invasive-fractional-flow-reserve-and-ffrct-100348722","NCT03820492","Comparison of Optical Coherence Tomography-derived Minimal Lumen Area, Invasive Fractional Flow Reserve and FFRCT","Multimodality Assessment of Intermediate Left Main Stenosis: Comparison of Optical Coherence Tomography-derived Minimal Lumen Area, Invasive Fractional Flow Reserve and FFRCT","OPTICO-LM","Inclusion Criteria:\n\n* Unprotected LM lesion \\[midshaft, and distal bifurcation (Medina 1,1,1 or 1,1,0 or 1,0,1 or 1,0,0)\\] of 30% to 80% angiographic diameter stenosis (DS) on visual estimation or equivocal disease by angiography.\n* Age ≥18 years.\n* Ability to give preliminary oral consent witnessed by an independent physician or sign written informed consent prior to any study-specific procedures.\n\nExclusion Criteria:\n\n* Significant distal lesions (\\>50% angiographic DS on visual estimation within the left anterior descending artery \\[LAD\\] or left circumflex artery \\[LCX\\], except for ostium of LAD or LCX or diseased side branch \\[e.g. diagonal branch, obtuse marginal branch\\])\n* Ostial LM disease.\n* Acute coronary syndrome (ACS) (non-ST-elevation ACS and ST-elevation MI).\n* LM In-stent restenosis.\n* Previous coronary stenting of the left coronary system.\n* Chronic total occlusion.\n* Previous coronary artery bypass graft.\n* Previous MI related to the left coronary artery.\n* Occurrence of ventricularization or hypotension during engagement of the LM ostial lesion.\n* The presence of hemodynamic instability.\n* Known renal insufficiency (serum creatinine \\>1.5mg\u002FdL or receiving dialysis).\n* Female of childbearing potential (age \\\u003C50 years and last menstruation within the last 12 months), who did not undergo tubal ligation, ovariectomy or hysterectomy.\n* Life expectancy less than 1 year.\n* Contraindication or known allergy against protocol-required medications including heparin, iodinated contrast, β-blocker, nitroglycerin, and adenosine.\n* Body mass index \\>35kg\u002Fm2.\n* Complex congenital heart disease other than anomalous coronary origins alone.\n* Ventricular septal defect.",{"count":503,"type":21},104,[59],"Significant left main (LM) stenosis is associated with a poor prognosis, therefore, adequate judgement of the prognostic significance of LM stenosis is essential to improve patients' prognosis. Recently, fractional flow reserve (FFR) has become widespread practice and carries a Class Ia recommendation to assess functional significance of intermediate coronary stenosis in patients with stable angina. Intravascular ultrasound (IVUS)-derived minimum lumen area (MLA) represents an accurate measure to determine LM significance as shown in multiple studies, while optical coherence tomography (OCT) ,which is a novel intracoronary imaging method with a greater spatial resolution (15μm vs. 100μm), faster image acquisition and facilitated image interpretation, OCT derived-MLA has never been validated against FFR and accordingly, it is not mentioned in the current guidelines for myocardial revascularization. Coronary computed tomography angiography (CTA) has emerged as a noninvasive alternative of coronary angiography with its excellent negative predictive value, while the positive predictive value of CTA is limited. Computational fluid dynamics is an emerging method that enables prediction of blood flow in coronary arteries and calculation of FFR from computed tomography (FFRCT) noninvasively. Noninvasive and accurate assessment of functional significance would bring a great benefit for patients with LM stenosis, however, there are no data to evaluate the diagnostic accuracy of FFRCT for LM stenosis in comparison with FFR and minimal lumen area derived by OCT.\n\nThis study will investigate the optimal OCT-derived MLA cut-off point and the diagnostic performance of FFRCT for intermediate LM stenosis compared with FFR ≤0.8 as a reference standard.",[25],[508,509,510,511],"Coronary artery disease","Fractional flow reserve","Optical coherence tomography","Computed tomography angiography","2023-02-08",{"date":514,"type":36},"2023-02-09",{"date":516,"type":36},"2019-05-28",{"date":312,"type":21},{"name":519,"class":43},"Insel Gruppe AG, University Hospital Bern",13,{"id":522,"slug":523,"hasResults":11,"nctId":524,"briefTitle":525,"officialTitle":526,"acronym":527,"eligibilityCriteria":528,"healthyVolunteers":11,"sex":17,"minAge":529,"maxAge":398,"enrollmentInfo":530,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":532,"conditions":533,"keywords":536,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":539,"lastUpdatePostDateStruct":540,"startDateStruct":542,"completionDateStruct":544,"leadSponsor":546,"locationsCount":548},"100478364","ai-driven-national-platform-for-ct-coronary-angiography-for-clinical-and-industrial-applications-registry-100478364","NCT05509010","AI Driven National Platform for CT cOronary Angiography for clinicaL and industriaL applicatiOns Registry","AI Driven National Platform for CT cOronary Angiography for clinicaL and industriaL applicatiOns Registry (APOLLO)","APOLLO","Inclusion Criteria:\n\n1. Age ≥21 years old\n2. Signed informed consent\n3. Clinically indicated for evaluation by CTCA\n\nExclusion Criteria:\n\n1. Individuals unable to provide informed consent\n2. Known complex congenital heart disease\n3. Planned invasive angiography for reasons other than CAD\n4. Non-cardiac illness with life expectancy \\\u003C 2 years\n5. Pregnancy\n6. Concomitant participation in another clinical trial in which subject is subject to investigational drug or device\n7. Cardiac event and\u002For coronary revascularization (percutaneous coronary intervention (PCI) and\u002For coronary artery bypass grafting (CABG) and\u002For valvular repair\u002Freplacement prior to CTCA\n8. Glomerular Filtration Rate ≤ 30mL\u002Fmin\n9. Known allergy to iodinated contrast agent\n10. Contraindications to beta blockers or nitroglycerin or adenosine","21 Years",{"count":531,"type":21},8000,"The overall aim is to build an AI driven national Platform for CT cOronary angiography for clinicaL and industriaL applicatiOns (APOLLO) for automated anonymization, reporting, Agatston scoring and plaque quantification in CAD. It is a \"one-stop\" platform spanning diagnosis to clinical management and prognosis, and aid in predicting pharmacotherapy response.",[534,92,25,535],"CAD","Plaques; Epicardial",[537,538],"CTCA","CT Coronary Angiography","2022-08-18",{"date":541,"type":36},"2022-08-19",{"date":543,"type":36},"2021-10-01",{"date":545,"type":21},"2027-12",{"name":547,"class":43},"National Heart Centre Singapore",3]